Ask VialBase
In vitro (multiple cell lines) · PMID 40908429

Epitalon dose-dependent telomere extension through hTERT and telomerase upregulation; ALT activation in cancer cells — VialBase Research

Dose-dependent telomere length extension in normal epithelial and fibroblast cells

Last updated · 2025 · Various · Biogerontology
Key findings
  • Dose-dependent telomere length extension in normal epithelial and fibroblast cells
  • Extension in normal cells via hTERT mRNA upregulation and telomerase activation
  • Cancer cells (21NT, BT474) showed telomere extension through ALT activation, not telomerase
  • Only minor ALT activity in normal cells -- cancer-cell specific
  • First quantitative study of epitalon's biomolecular pathway in multiple cell types

Epitalon Telomere Extension: Normal vs Cancer Cells (PMID: 40908429)

Study Design

  • Cell lines: breast cancer (21NT, BT474), normal epithelial, normal fibroblast
  • Dose-response experiments with epitalon
  • Measured: telomere length (qPCR), hTERT mRNA expression, telomerase activity, ALT activation (immunofluorescence)

Key Results

  • Normal cells: Dose-dependent telomere extension via hTERT upregulation and telomerase activation
  • Cancer cells: Significant telomere extension BUT through ALT (Alternative Lengthening of Telomeres), not telomerase
  • Critical distinction: ALT activation was specific to cancer cells; only minor ALT in normal cells
  • First study to quantify these distinct pathways in different cell types

Safety Implications

The ALT activation in cancer cells is a double-edged sword:

  • Does NOT suggest epitalon causes cancer
  • DOES suggest that existing cancer cells may benefit from an alternative telomere maintenance mechanism
  • Recommends avoiding Epithalon in active malignancy

Relevance

Foundational study validating Epithalon‘s telomerase-activating mechanism while identifying an important safety nuance for cancer patients.

See Also

View on PubMed · PMID 40908429 →